Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Spyre Therapeutics, Inc. (SYRE)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2017
2018
2019
2020
2021
2022
2023
2024
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $886,000 | $2.3M | $18.7M | $0 | $0 | $3.9M | $5.2M | $4.6M | — | — |
| Research & development | $171.7M | $162.8M | $89.5M | $58.6M | $57.1M | $59.6M | $64.6M | $36.7M | $22.8M | $18.1M | $11.5M | $6.8M |
| Operating expenses | $209.6M | $208.6M | $243.2M | $87.1M | $84.4M | $81.5M | $80.3M | $49.4M | $32.9M | $26.5M | $17.4M | $8.9M |
| Operating income | −$209.6M | −$208.6M | −$242.3M | −$84.8M | −$65.6M | −$81.5M | −$80.3M | −$45.5M | −$27.7M | −$21.9M | −$11.3M | −$8.9M |
| EBITDAderived | −$209.6M | −$208.6M | −$241.6M | −$83.2M | −$64.1M | −$80.5M | −$79.9M | −$45.2M | −$27.4M | −$21.8M | −$11.2M | −$8.9M |
| Net income | −$155.2M | −$208.0M | −$338.8M | −$83.8M | −$65.8M | −$80.9M | −$78.3M | −$44.3M | −$27.2M | −$21.7M | −$11.3M | −$10.3M |
| Basic EPSper diluted share | — | — | $13.76 | -$24.86 | -$25.02 | -$1.52 | -$2.45 | -$2.13 | -$1.80 | -$2.22 | -$19.21 | — |
| Diluted EPSper diluted share | — | — | $13.76 | -$24.86 | -$25.02 | -$1.52 | -$2.45 | -$2.13 | -$1.80 | -$2.22 | -$19.21 | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 25, 2026Form 4 | Burrows Scott LChief Financial Officer | SellCommon Stock | 10.0K | $87.14 | $871.4K | 98.0K |
| Jun 25, 2026Form 4 | Burrows Scott LChief Financial Officer | SellCommon Stock | 5.0K | $87.12 | $435.6K | 108.0K |
| Jun 23, 2026Form 4 | Fairmount Funds Management LLC +3Director | SellCommon Stock · indirect | 4.68M | $85.31 | $399.66M | 0 |
| Jun 22, 2026Form 4 · 10b5-1 | HENDERSON MICHAEL THOMASDirector | SellCommon Stock | 20.0K | $100.00 | $2.00M | 68.6K |
| Jun 3, 2026Form 4 · 10b5-1 | Sloan SheldonChief Medical Officer | SellCommon Stock | 8.3K | $75.00 | $625.0K | 0 |